Hanx Biopharmaceuticals (3378) Announces Extraordinary General Meeting Agenda

Bulletin Express01-27

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Stock Code: 3378) has released details for an Extraordinary General Meeting (EGM) scheduled for 10:00 a.m. on Thursday, February 12, 2026. The meeting will convene at the company’s conference room on the third floor of Building A8, Phase II of the Bio-Innovation Park in Wuhan.

The EGM seeks shareholder approval of a single special resolution: granting a general mandate to the Board to repurchase the company’s H Shares during the defined Relevant Period. The circular dated January 27, 2026, provides more information on this proposal, which requires approval by at least two-thirds of the voting rights held by shareholders or their proxies present at the meeting.

Shareholders intending to appoint a proxy are required to submit a valid proxy form to the H share registrar, Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong), by 10:00 a.m. on Wednesday, February 11, 2026. Those planning to attend in person retain the right to vote on-site, rendering any previously assigned proxy nullified upon attendance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162715402?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162715402","market":"hk","top_or_hot":-1,"title":"Hanx Biopharmaceuticals (3378) Announces Extraordinary General Meeting Agenda","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Stock Code: 3378) has released details for an Extraordinary General Meeting (EGM) scheduled for 10:00 a.m. on Thursday, February 12, 2026. The meeting will convene at the company’s conference room on the third floor of Building A8, Phase II of the Bio-Innovation Park in Wuhan.</p>\n<p>The EGM seeks shareholder approval of a single special resolution: granting a general mandate to the Board to repurchase the company’s H Shares during the defined Relevant Period. The circular dated January 27, 2026, provides more information on this proposal, which requires approval by at least two-thirds of the voting rights held by shareholders or their proxies present at the meeting.</p>\n<p>Shareholders intending to appoint a proxy are required to submit a valid proxy form to the H share registrar, Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong), by 10:00 a.m. on Wednesday, February 11, 2026. Those planning to attend in person retain the right to vote on-site, rendering any previously assigned proxy nullified upon attendance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals (3378) Announces Extraordinary General Meeting Agenda</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals (3378) Announces Extraordinary General Meeting Agenda\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-01-27 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Stock Code: 3378) has released details for an Extraordinary General Meeting (EGM) scheduled for 10:00 a.m. on Thursday, February 12, 2026. The meeting will convene at the company’s conference room on the third floor of Building A8, Phase II of the Bio-Innovation Park in Wuhan.</p>\n<p>The EGM seeks shareholder approval of a single special resolution: granting a general mandate to the Board to repurchase the company’s H Shares during the defined Relevant Period. The circular dated January 27, 2026, provides more information on this proposal, which requires approval by at least two-thirds of the voting rights held by shareholders or their proxies present at the meeting.</p>\n<p>Shareholders intending to appoint a proxy are required to submit a valid proxy form to the H share registrar, Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong), by 10:00 a.m. on Wednesday, February 11, 2026. Those planning to attend in person retain the right to vote on-site, rendering any previously assigned proxy nullified upon attendance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1162715402","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162715402","pubTimestamp":1769521521,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Stock Code: 3378) has released details for an Extraordinary General Meeting (EGM) scheduled for 10:00 a.m. on Thursday, February 12, 2026. The meeting will...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克斯生物制药(3378)公布股东特别大会议程","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Stock Code: 3378) has released details for an Extraordinary General Meeting (EGM) scheduled for 10:00 a.m. on Thursday, February 12, 2026. The meeting will convene at the company’s conference room on the third floor of Building A8, Phase II of the Bio-Innovation Park in Wuhan.\nThe EGM seeks shareholder approval of a single special resolution: granting a general mandate to the Board to repurchase the company’s H Shares during the defined Relevant Period. The circular dated January 27, 2026, provides more information on this proposal, which requires approval by at least two-thirds of the voting rights held by shareholders or their proxies present at the meeting.\nShareholders intending to appoint a proxy are required to submit a valid proxy form to the H share registrar, Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong), by 10:00 a.m. on Wednesday, February 11, 2026. Those planning to attend in person retain the right to vote on-site, rendering any previously assigned proxy nullified upon attendance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162715402","isCrawlerRequest":true}